Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulatory News In Brief

This article was originally published in The Gray Sheet

Executive Summary

Primary mode of action: FDA lengthens the deadline for receiving stakeholder comments on the agency's proposed rule defining "mode of action" and "primary mode of action" to Aug. 20, following AdvaMed request for a 60-day extension, according to a June 24 Federal Register notice. FDA issued the proposed rule clarifying the mechanism for assigning jurisdiction of combination products May 7 (1"The Gray Sheet" May 10, 2004, p. 12). Comments initially were due July 6...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020480

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel